IND.216: a phase II study of buparlisib and associated biomarkers, raptor and p70S6K, in patients with relapsed and refractory chronic lymphocytic leukemia

TY - JOUR

T1 - IND.216

T2 - a phase II study of buparlisib and associated biomarkers, raptor and p70S6K, in patients with relapsed and refractory chronic lymphocytic leukemia

N1 - Publisher Copyright: © 2020, © 2020 Informa UK Limited, trading as Taylor & Francis Group.

PY - 2020/6/6

Y1 - 2020/6/6

KW - Chronic lymphocytic leukemia

KW - PI3K

KW - buparlisib

KW - clinical trial

KW - raptor

UR - http://www.scopus.com/inward/record.url?scp=85081371257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85081371257&partnerID=8YFLogxK

U2 - 10.1080/10428194.2020.1734594

DO - 10.1080/10428194.2020.1734594

M3 - Article

C2 - 32154751

AN - SCOPUS:85081371257

SN - 1042-8194

VL - 61

SP - 1653

EP - 1659

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 7

ER -